FDA's Decade Of TNF Blocker Experience Eased Path For Simponi Approval

FDA’s first-cycle approval of Centocor’s TNF inhibitor Simponi (golimumab) encapsulates the double-edged position of late entrants into crowded drug classes: while differentiating a new product may pose a commercial challenge, FDA’s experience with early members of the class can smooth the way to approval for late-comers.